Answers are grounded in this paper and cite their sources.
Malaria remains a severe mosquito-borne disease that heavily impacts infants and young children in tropical and subtropical regions. Because their immune systems are still developing, infants face a high risk of life-threatening complications, including severe anemia, hypoglycemia, and cerebral malaria [1-12]. Artemisinin and its derivatives such as artesunate, artemether, and dihydroartemisinin have transformed malaria care by rapidly killing Plasmodium falciparum parasites [29-31]. Today, healthcare providers use artemisinin-based combination therapies (ACTs) as the standard treatment for uncomplicated malaria, while relying on parenteral artesunate to treat severe cases in infants [29-31]. Despite their advantages, artemisinin derivatives present clinical limitations such as a short biological half-life, poor bioavailability, and emerging resistance linked to PfK13 gene mutations [35,41-55]. This review summarizes the pharmacology, mechanism of action, clinical applications, dosage scaling considerations, and resistance patterns of artemisinin in infant populations. The findings underscore the continued importance of ACTs in pediatric malaria management while highlighting the critical need for continuous resistance surveillance, dosing optimization in malnourished pediatric cohorts, and the development of child-friendly formulations [29,30,50-55].
No takes yet. Share an insight, caveat, or question.
M. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: